retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial is gaining attention in metabolic retatrutide ly3437943 triple agonist glp-1

Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese adults with obesity achieved the 24-week primary endpoint

[Neuroinflammation in the brain of patients with myalgic encephalomyelitis/chronic fatigue syndrome]

Step 5: Follow-Up Care Weekly or bi-weekly sessions may be advised for sustained results

When appropriate and with patient consent, I find it valuable to understand the broader treatment context, including how long a patient has been on therapy, whether dosing has changed recently, and what the anticipated long-term plan looks like, since all of these factors shape what aesthetic approach makes the most sense at a given point in time

Melanocytes continue producing eumelanin for 35 days after the last MC1R activation, and that melanin takes 2830 days to turn over as keratinocytes shed

Novel drugs approved by the EMA, FDA, and MHRA in 2023